Back to resultsUse of FDG PET as Predictor of Residual Disease and Subsequent Relapse in Patients With NHL and HD Undergoing HDC and ASCT
Primary Purpose
Lymphoma, Non-Hodgkin, Hodgkin Disease
Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
FDG PET
Sponsored by
About this trial
This is an interventional treatment trial for Lymphoma, Non-Hodgkin focused on measuring NHL and HD
Eligibility Criteria
Inclusion Criteria:
- Patients with NHL and HD undergoing HDC and ASCT
Sites / Locations
Outcomes
Primary Outcome Measures
Prognosis
Secondary Outcome Measures
Full Information
NCT ID
NCT00534989
First Posted
September 24, 2007
Last Updated
December 16, 2015
Sponsor
King Faisal Specialist Hospital & Research Center
1. Study Identification
Unique Protocol Identification Number
NCT00534989
Brief Title
Use of FDG PET as Predictor of Residual Disease and Subsequent Relapse in Patients With NHL and HD Undergoing HDC and ASCT
Official Title
Use of FDG PET as Predictor of Residual Disease and Subsequent Relapse in Patients With NHL and HD Undergoing HDC and ASCT
Study Type
Interventional
2. Study Status
Record Verification Date
December 2015
Overall Recruitment Status
Completed
Study Start Date
September 2007 (undefined)
Primary Completion Date
February 2013 (Actual)
Study Completion Date
December 2013 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
King Faisal Specialist Hospital & Research Center
4. Oversight
5. Study Description
Brief Summary
Cytogenetic Analysis of Bone Marrow Specimen Prior to High Dose Chemotherapy and Autologous Stem Cell Transplantation in Patients with Non-Hodgkin's Lymphoma or Hodgkin's Disease
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Lymphoma, Non-Hodgkin, Hodgkin Disease
Keywords
NHL and HD
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
10 (Actual)
8. Arms, Groups, and Interventions
Intervention Type
Procedure
Intervention Name(s)
FDG PET
Intervention Description
FDG PET
Primary Outcome Measure Information:
Title
Prognosis
Time Frame
overall
10. Eligibility
Sex
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients with NHL and HD undergoing HDC and ASCT
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Syed Akhtar, MD
Organizational Affiliation
KFSH & RC
Official's Role
Principal Investigator
12. IPD Sharing Statement
Learn more about this trial
Use of FDG PET as Predictor of Residual Disease and Subsequent Relapse in Patients With NHL and HD Undergoing HDC and ASCT
We'll reach out to this number within 24 hrs